According to a new report, published by KBV research, The Global Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market size is expected to reach $2.8 billion by 2030, rising at a market growth of 8.4% CAGR during the forecast period.
The Assays & Kits segment acquired the maximum revenue share in the Global Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Product in 2022, thereby achieving a market value of $2 billion by 2030. Assays and kits are in constant and higher demand than tools for disease diagnosis, which primarily drives this segment's continuous expansion. Assay & Kits are commonly purchased, leading to a high constant buy that directly contributes to this product segment's vast size and rapid expansion.
The Hospitals & Clinics segment has shown the high growth rate of 8.6% during (2023 - 2030). This segment has experienced tremendous market expansion, mostly due to a greater focus on early disease treatments. Hospitals are dedicated to giving patients specialized treatment to people with CT/NG. patients prefer hospitals over diagnostic laboratories as mostly hospitals offer both diagnostic and treatment facilities.
The Lab Tests segment is leading the Global Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Testing Type in 2022, thereby achieving a market value of $1.9 billion by 2030. In comparison to PoC tests, lab tests are more sensitive and specific. A controlled lab setting ensures more precise and sensitive measurements, lowering the possibility of false-negative or false-positive results. Another benefit of lab tests is the capacity to process a larger number of samples concurrently. These elements should encourage the expansion of this segment.
The Polymerase Chain Reaction segment is showcasing a CAGR of 8.7% during (2023 - 2030). It is a method that rapidly and precisely replicates many copies of a particular DNA sequence. Investigators need to extract huge quantities of DNA for numerous investigations and methods in molecular biology, forensic science, evolutionary biology, and medical diagnostics. The process of polymerase chain reaction makes this feasible.
The North America region dominated the Global Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Testing Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1.1 billion by 2030. The Europe market is poised to grow at a CAGR of 7.9% during (2023 - 2030). Additionally, The Asia Pacific market would display a CAGR of 9.2% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/chlamydia-trachomatis-neisseria-gonorrhoeae-testing-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Becton, Dickinson and Company, ZeptoMetrix LLC (Antylia Scientific), Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Thermo Fisher Scientific, Inc., Bayer AG, Qiagen N.V. and Siemens AG.
By Product
By End User
By Testing Type
By Technology
By Geography
Companies Profiled
Unique Offerings 
